Mylan Launches Generic Adderall

NOVEMBER 25, 2015
Krystle Vermes
Mylan has launched a generic version of Teva Pharmaceuticals’ Adderall in 5 mg, 7.5 mg, 10 mg, 12.5 mg, 20 mg, and 30 mg doses.

The tablets indicated for treating attention deficit hyperactivity disorder (ADHD) consist of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate.

Last year, sales of the drug for the fiscal year ending on September 30, 2015, totaled around $570 million, according to IMS Health.

Adverse effects associated with Adderall include nervousness, restlessness, difficulty sleeping, chest pain, hallucinations, and headache.

In many instances, patients with Tourette syndrome, severe anxiety, or history of glaucoma are advised to avoid Adderall due to the adverse effects.

Amphetamines have a high potential for abuse, so prolonged use may lead to dependence, Mylan noted in a press release. In addition, misuse of amphetamine can result in sudden death or adverse cardiovascular events.

Mylan currently has 253 abbreviated new drug applications pending FDA approval that are worth around $100 billion in brand sales, according to IMS Health.